Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

RNS - Eckert & Ziegler Selected as US Manufacturer for Archeus Next-Generation Radiopharmaceutical ART-101

Company: Eckert & Ziegler Strahlen- und Medizintechnik AG Date: 2025-07-29 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 News Details 

Corporate | 29 July 2025 14:00

#   

Eckert & Ziegler Selected as US Manufacturer for Archeus’ Next-Generation Radiopharmaceutical ART-101

Eckert & Ziegler SE / Key word(s): Incoming Orders/Agreement  

Eckert & Ziegler Selected as US Manufacturer for Archeus’ Next-Generation Radiopharmaceutical ART-101  

  

29.07.2025 / 14:00 CET/CEST  

The issuer is solely responsible for the content of this announcement.  

  

- - -

Berlin, Germany, 29 July 2025. Eckert & Ziegler (ISIN DE0005659700) has entered a Master Service Agreement with Archeus Technologies (Archeus), a company developing multiple differentiated radiopharmaceutical therapies, for contract manufacturing of its novel investigational compound ART-101. The agreement supports Archeus’ upcoming Phase 1 clinical trial of ART-101 in the United States, with manufacturing to be performed at Eckert & Ziegler’s state-of-the-art GMP facility in Boston, MA.  

  

ART-101 is a next-generation small molecule that targets prostate-specific membrane antigen (PSMA) and is in development for the imaging and treatment of prostate cancer. Preclinical studies suggest ART-101 may offer enhanced pharmacology and tolerability compared to existing PSMA-targeted therapies.  

  

“We are pleased to partner with Archeus on the clinical development of ART-101,” commented Dr. Harald Hasselmann, Chief Executive Officer of Eckert & Ziegler SE. “Our GMP-certified Boston facility is ideally equipped to support their early-phase development needs. This collaboration reflects our broader commitment to advancing next-generation targeted radiotherapies through high-quality manufacturing and clinical supply services.”  

  

“Eckert & Ziegler’s GMP infrastructure, operational reliability, and radiopharmaceutical manufacturing expertise enable Archeus to quickly and confidently advance ART-101 into first-in-human trials this year,” added Evan Sengbusch, Ph.D., Chief Executive Officer of Archeus Technologies.  

  

The collaboration is an important milestone in the ongoing efforts of both companies to advance the development of innovative solutions in the radiopharmaceutical field. Eckert & Ziegler operates several CMO sites worldwide and offers a range of other services along the entire value chain including the supply of high-quality radioisotopes.  

  

**About Eckert & Ziegler**  

Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.  

**Contributing to saving lives  

  

Contact**  

Eckert & Ziegler SE  

Robert-Rössle-Str. 10, 13125 Berlin, Germany  

Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations  

[jan.schoepflin@ezag.de](mailto:jan.schoepflin@ezag.de) / [karolin.riehle@ezag.de](mailto:karolin.riehle@ezag.de)  

Tel.: +49 (0) 30 / 94 10 84-138; [www.ezag.com](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=9373c2b23d4e95eaa5896890af5281a0&application_id=2175320&site_id=airport_aws~~~7cc68db1-74de-43c8-af69-2ae0a97efdc3&application_name=news)

  

- - -

29.07.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.  

The issuer is solely responsible for the content of this announcement.  

  

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.  

Archive at www.eqs-news.com  

- - -

|     |     |
| --- | --- |
| Language: | English |
| Company: | Eckert & Ziegler SE |
|     | Robert-Rössle-Str.10 |
|     | 13125 Berlin |
|     | Germany |
| Phone: | +49 30 941084-138 |
| Fax: | +49 30 941084-0 |
| Internet: | www.ezag.de |
| ISIN: | DE0005659700 |
| WKN: | 565970 |
| Indices: | SDAX, TecDax, |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2175320 |

  

|     |     |
| --- | --- |
|     |     |
| End of News | EQS News Service |

- - -

2175320  29.07.2025 CET/CEST

![](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2175320&application_name=news&site_id=airport_aws~~~7cc68db1-74de-43c8-af69-2ae0a97efdc3)

Unlock Europe's Largest Financial Database—Free

Get instant access to over 2.8M filings from 8,970 companies across 44 markets. No cost. No hassle. Just results.